Former NIH Director Francis Collins Retires, Marking End of Era in Biomedical Research

Francis Collins, M.D., Ph.D., a prominent figure in biomedical research, has retired from the National Institutes of Health (NIH) after a distinguished 32-year career. Collins, who served as NIH director from 2009 to 2021 under three presidents, officially concluded his tenure on February 28, 2025.

Collins' Legacy and Contributions to Biomedical Research

During his time at the NIH, Collins made significant contributions to the field of biomedical research. As director of the National Human Genome Research Institute from 1993 to 2008, he led the Human Genome Project, which successfully completed the compilation of a full human genome in 2003. This groundbreaking achievement laid the foundation for numerous advancements in genetics and personalized medicine.

Collins' research group focused on two key areas: type 2 diabetes and progeria, a rare disease causing premature aging. Their work on progeria contributed to the development of the first approved therapy for the condition, Zokinvy (lonafarnib), now marketed by Sentynl Therapeutics.

NIH Leadership Changes and Industry Impact

Collins' retirement comes amid a series of departures from federal health agencies following the re-election of President Donald Trump. Other recent exits include NIH Deputy Director for Extramural Research Michael Lauer, M.D., and Principal Deputy Director Larry Tabak, Ph.D.

These leadership changes coincide with broader shifts in the pharmaceutical and biomedical research landscape. The new administration has implemented significant changes, including:

• Termination of numerous federal employees
• Cancellation of research grants
• Closure of 30 FDA facilities across 23 states, overseen by the newly established Department of Government Efficiency led by Elon Musk

Collins' Parting Words and Vision for NIH

In his retirement statement, Collins expressed deep admiration for the NIH, describing it as the "crown jewel" of the federal government and the "main piston of a biomedical discovery engine that is the envy of the globe."

He emphasized the critical role of NIH employees, stating that they "deserve the utmost respect and support of all Americans." This sentiment underscores the challenges facing the agency amidst ongoing changes in federal health policy and funding.

As the pharmaceutical industry adapts to these shifts in leadership and policy, Collins' departure marks the end of an era in biomedical research and sets the stage for a new chapter in the NIH's storied history.